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Abstract
Purpose: Obese subjects with nonalcoholic fatty liver disease (NAFLD) are more prone to 
develop additional metabolic disturbances such as systemic insulin resistance (IR) and 
type 2 diabetes. NAFLD is defined by hepatic steatosis, lobular inflammation, ballooning 
and stage of fibrosis, but it is unclear if and which components could contribute to IR.
Objective: To assess which histological components of NAFLD associate with IR in subjects 
with obesity, and if so, to what extent.
Methods: This cross-sectional study included 78 obese subjects (mean age 46 ± 11 years; 
BMI 42.2 ± 4.7 kg/m2). Glucose levels were analysed by hexokinase method and insulin 
levels with electrochemiluminescence. Homeostasis model assessment-estimated insulin 
resistance (HOMA-IR) was calculated. Liver biopsies were evaluated for histological 
components of NAFLD.
Results: A positive association between overall NAFLD Activity Score and HOMA-IR 
was found (rs = 0.259, P = 0.022). As per individual components, lobular inflammation 
and fibrosis stage were positively associated with HOMA-IR, glucose and insulin levels 
(P < 0.05), and HOMA-IR was higher in patients with more inflammatory foci or higher 
stage of fibrosis. These findings were independent of age, BMI, triglyceride levels, 
diabetes status and sex (all P < 0.043). In a combined model, lobular inflammation, but 
not fibrosis, remained associated with HOMA-IR.
Conclusion: In this group of obese subjects, a major contributing histological component 
of NAFLD to the relation between NAFLD severity and IR seems to be the grade of hepatic 
lobular inflammation. Although no causal relationship was assessed, preventing or 
mitigating this inflammatory response in obesity might be of importance in controlling 
obesity-related metabolic disturbances.
Introduction
An important complication of obesity is the development 
of nonalcoholic fatty liver disease (NAFLD), which covers 
a broad histological spectrum from simple steatosis to 
nonalcoholic steatohepatitis (NASH), and can progress 
to fibrosis, cirrhosis and even hepatocellular carcinoma. 
Nonalcoholic fatty liver (NAFL) is diagnosed when 
steatosis is present in >5% of the hepatocytes with 
or without nonspecific mild lobular inflammation, 
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while patients with NASH require the joint presence of 
steatosis along with ballooning and lobular inflammation 
(1, 2). To date, liver biopsy is the reference standard for 
diagnosis of NAFLD stage and quantification of histological 
components of NAFLD. Currently, two frequently used 
evaluation methods are NAFLD Activity Score (NAS) and 
Steatosis, Activity, and Fibrosis (SAF) score (3).
Importantly, patients with obesity who develop 
NAFLD are also more prone to develop other metabolic 
consequences of obesity such as insulin resistance 
(IR) and subsequently type 2 diabetes (T2D) (4). The 
pathogenesis of NAFLD is complex whereby the historical 
two-hit hypothesis is replaced by a multiple parallel 
hits hypothesis also considering the impact of an 
altered adipokine secretory pattern, inflammation, gut 
microbiota, nutritional factors, genetic and epigenetic 
factors, and IR on the development and progression of 
NAFLD (5, 6). Especially this interrelation between IR and 
NAFLD is intriguing, as IR can be modified, and may lead 
to T2D. Recent experimental work suggested that excess 
accumulation of diacylglycerol (DAG) in hepatocytes, 
rather than hepatic steatosis per se (intrahepatic triglyceride 
(TG) content), is the main molecular mechanism of 
development of IR (7, 8). Until now, however, few human 
studies investigated the association between IR and 
individual histological components of NAFLD (steatosis, 
lobular inflammation, ballooning and fibrosis) (9, 10, 11, 
12, 13, 14, 15). Moreover, most of these studies were not 
primarily designed to investigate IR, included non-obese 
or paediatric subjects, and yielded contradictory overall 
results. As an increase in knowledge and understanding 
of the complex relation between IR and NAFLD could 
lead to possible new therapeutic pathways or targets, 
we addressed this association specifically in a high-risk, 
severely obese population with histological evaluation 
of NAFLD.
Materials and methods
Study design and subjects
In a cross-sectional study (registration number 
B67020084018), 71 men with obesity who were scheduled 
for gastric bypass surgery (GBS) were included. These men 
met the national reimbursement criteria for GBS since 
they had either a BMI >40 kg/m2 or a BMI >35 kg/m2  
with at least one of the following co-morbidities – T2D, 
obstructive sleep apnoea, therapy-resistant arterial 
hypertension. Exclusion criteria were malignancies, 
drinking more than three units alcohol per day, 
known liver pathologies other than NAFLD, and a recent 
diagnosis of hypo- or hyperthyroidism or a recent change 
in their medication. In total 16 subjects were excluded 
from the analysis; due to use of GLP-1 analogue (n = 1) 
or insulin (n = 7), refusing liver biopsy (n = 1), no scored 
liver biopsy (n = 4), no blood samples available (n = 1), 
or no pre-surgical blood samples (n = 2). In addition, 
24 subjects with obesity were recruited in another study 
(registration number B670201526667) which had the 
same inclusion and exclusion criteria. One patient refused 
a liver biopsy. These 23 subjects consisted of 8 women 
and 15 men. Four of them started a conservative weight 
loss programme, the other 19 subjects underwent GBS. In 
both studies, glucose-lowering medication (for example, 
two subjects were on sulphonylurea and one subject used 
a DPP4-inhibitor) was discontinued at least 24 h before 
surgery. None of the subjects used vitamin E supplements, 
thiazolidinediones or known steatogenic medication. 
During the pre-operative period, body weight was stable, 
and no subjects used a very low caloric diet. Thus, a total 
of 78 subjects with obesity who underwent liver biopsy 
were available for analysis. All participants gave written 
informed consent to participate in these studies, which 
were approved by the Ethical Review Board of the Ghent 
University Hospital and conducted according to the 
principles of the Declaration of Helsinki.
Anthropometrics and general characteristics
For all subjects standing height was measured to the 
nearest 0.1 cm using a wall-mounted stadiometer. Body 
weight was measured to the nearest 0.1 kg on a calibrated 
scale in light indoor clothing without shoes. Subsequently, 
BMI was calculated. T2D was defined according to the 
ADA criteria (16). Medication use was retrieved from the 
patients’ records and double checked by questioning 
the patient.
Biochemical measurements
Blood samples were collected after overnight fasting. All 
blood samples were centrifuged, serum was fractionated 
and stored at −80°C until further analysis.
Serum levels of fasting glucose were analysed by the 
hexokinase method (COBAS, Roche Diagnostics). Insulin 
levels were determined with electrochemiluminescence 
using the immunoanalyzer COBAS e411 (Roche 
Diagnostics). Homeostasis model assessment-estimated 
insulin resistance (HOMA-IR) was calculated using the 
following formula (17): 
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HOMA-IR
fasting glucose (mmol/L) fasting insulin ( U/mL)
=
× µ
22 5.
 
C-reactive protein (CRP), TG, cholesterol and high-
density lipoproteins (HDL) were routinely determined 
using standard laboratory assays (COBAS 8000 modular 
analyser series, Roche Diagnostics, Mannheim, Germany). 
Low-density lipoproteins (LDL) was calculated using the 
Friedman formula: 
LDL cholesterol (mg/dL)
TG (mg/dL)
HDL (mg/dL)= − −
5
Non-esterified fatty acids (NEFAs) were determined 
with the standard enzymatic colorimetric method 
(P-modular; Roche Diagnostics).
Hepatic histopathological analysis
Liver biopsies from the four patients following 
the conservative approach were taken, guided by 
ultrasonography using a biopsy gun with an 18-gauge 
needle (Bard Magnum, Tempe, AZ, USA) after local 
anaesthesia with 2% xylocaine. In the other participants, 
a liver biopsy was carried out at the end of the GBS 
procedure, which measured at least 5 × 5 mm and was 
taken from the lateral edge of the left liver lobe. All 
biopsies were immediately fixed in formalin (buffered 
4% formaldehyde solution, Klinipath, Belgium) at room 
temperature for microscopic analysis. The formalin-fixed, 
paraffin-embedded tissue sections were stained with 
hematoxylin and eosin (H&E) and Sirius red and scored 
by experienced pathologists (MP and AH). Steatosis was 
assessed by the percentage of hepatocytes containing 
large and medium-sized intracytoplasmic lipid droplets 
(but not foamy microvesicles), on a scale of 0 to 3 (0, <5%; 
1, 5–33%; 2, >33–66%; 3, >66%). Lobular inflammation 
was scored at 20× magnification ranging from 0 to 3 
(0, none; 1, <2 foci per 20× field; 2, 2–4 foci per 20× field; 
3, >4 foci per 20× field) when applying the NASH CRN 
scoring system (18). When applying the Steatosis, Activity, 
Fibrosis score (SAF score) system, a three-tiered scoring 
for lobular inflammation was performed ranging from 0 
to 2 (0, none; 1, ≤2 foci per 20×; 2, >2 foci per 20×) (19). 
Hepatocellular ballooning was scored from 0 to 2 (0 = none, 
1 = few, 2 = many) and fibrosis scored from 0 to 4 (0 = none, 
1 = perisinusoidal or (peri)portal, 2 = perisinusoidal and 
(peri)portal, 3 = bridging fibrosis, 4 = cirrhosis; not available 
in one participant). Consequently, the NAFLD Activity 
Score (NAS) and SAF score could be determined. NAS is the 
unweighted sum of steatosis grade, lobular inflammation 
and ballooning and receives a score ranging from 0 to 8. 
Most cases diagnosed as steatosis have a total NAS score 
of ≤2, while most cases diagnosed as steatohepatitis have 
a total score of ≥5. A total score of 3 or 4 can be either 
steatosis or steatohepatitis. However, NAS has not been 
developed to establish a diagnosis of NASH, but it is rather 
a continuous scale of the NASH activity assessment and 
has thus been used as such in our study (20). Recently, 
the SAF score has been developed in order to categorise 
obesity-associated liver disease (21). It assesses the grade 
of steatosis (S, from S0 to S3), the grade of activity (A from 
A0 to A4 by the addition of grades of ballooning and 
lobular inflammation) and the stage of fibrosis (F from 
F0 to F4). All patients who received a diagnosis of NASH 
had >5% steatosis in hepatocytes and a grade of activity 
A ≥ 2 (19, 22).
Statistical analysis
Data were evaluated for normality of distribution and 
if necessary, logarithmically transformed. Data are 
presented as mean ± s.d. for normally distributed data 
and median (25% percentile–75% percentile) for non-
Gaussian distributed data. Kruskal–Wallis tests with 
Mann–Whitney U post hoc tests for continuous variables 
and the Fisher’s exact test for categorical variables were 
used for comparison between groups based on the liver 
parameters (NAS, SAF, grade of steatosis, ballooning, 
inflammation and fibrosis stage). Spearman correlations 
were performed to investigate the associations between 
liver parameters and IR. Groups with less than five 
participants were excluded from analysis. Furthermore, 
one-way ANCOVA was conducted to evaluate the 
differences in HOMA-IR levels while controlling for age, 
BMI, TG, T2D status, sex and histological components. 
For ANCOVA the dependent variable was logarithmically 
transformed. For each ANCOVA output residual plots 
were made and outliers were removed from the analysis. 
Test results were considered statistically significant at 
P values <0.05. IBM SPSS statistics (version 25, Chicago, 
IL, USA) was used for all statistical analysis.
Results
General characteristics of participants as a whole group 
and according to SAF-derived NASH status are shown in 
Table 1. In our cohort, all participants were Caucasian, and 
16 subjects (21%) had T2D. Only five participants had no 
obesity-associated liver disease, 33 had NAFL and 40 NASH 
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according to the SAF score; distribution of participants 
according to the histopathological components is given 
in Table 2. Compared to patients with NAFL or without 
liver disease, patients with NASH showed a trend toward a 
lower BMI and had higher glucose and TG levels (Table 1). 
In the whole group, HOMA-IR was positively associated 
with NAS (Fig. 1), and a trend toward higher HOMA-IR 
with a more severe SAF classification (rs = 0.212, P = 0.062) 
was observed.
There were no differences in HOMA-IR or insulin 
levels between groups according to grade of steatosis (for 
HOMA-IR Fig. 2, panel A), whereas higher glucose levels 
were found in patients with steatosis grade >33–66% 
compared to those with a lower (P = 0.002) or higher 
(P = 0.021) steatosis grade. Similarly, no differences in 
insulin levels or HOMA-IR were found according to 
ballooning status, but participants with few ballooning 
had higher glucose levels compared to those without 
(Fig. 2, panel B). In contrast, HOMA-IR and insulin, but 
not glucose levels, were higher in patients with more 
inflammatory foci compared to those with less (Fig. 2, 
panel C), and patients with fibrosis score 1 or 2 had higher 
glucose levels (P = 0.006 and P = 0.042, respectively) and 
showed trends towards higher insulin levels and HOMA-IR 
(Fig. 2, panel D) as compared to those with score 0.
Univariate correlations yielded similar results and 
are shown in Table 3. Steatosis score was not associated 
with glucose, insulin or HOMA-IR levels; ballooning 
score correlated positively with glucose levels only; and 
lobular inflammation and fibrosis stage showed positive 
correlations with glucose and insulin levels and with 
HOMA-IR.
Finally, multivariate analyses showed that the 
difference in HOMA-IR according to grade of lobular 
inflammation was independent of age and BMI 
(F(2,72) = 5447; P = 0.005); age, BMI and TG (F(2,70) = 5304; 
P = 0.007); age, BMI and sex (F(2,71) = 5436; P = 0.006); 
age, BMI and T2D status (F(2,71) = 3014, P = 0.040); 
Table 1 General descriptives of the whole cohort and for SAF groups separately.
All (n = 78) No NAFLD (n = 5) NAFL (n = 33) NASH (n = 40) P value
Age (years) 46 ± 11 42 ± 15 45 ± 12 47 ± 9 0.581
BMI (kg/m2) 42.2 ± 4.7 44.0 ± 4.9 43.3 ± 4.4 41.0 ± 4.7 0.073
Sex (male/female) 70/8 3/2 29/4 38/2 0.061
T2D (yes/no) 16/62 0/5 1/32 15/25 <0.001
CRP (nmol/L) 40.0 (21.0–61.9) 59.1 (41.9–76.2) 40.0 (25.7–61.9) 37.6 (20.0–57.6) 0.618
Cholesterol (mmol/L)a 4.99 ± 1.09 4.50 ± 0.12 4.82 ± 1.03 5.25 ± 1.20 0.431
LDL (mmol/L)a 2.86 ± 0.81 2.58 ± 0.29 2.87 ± 0.87 2.89 ± 0.80 0.754
HDL (mmol/L)a 1.02 ± 0.33 1.09 ± 0.23 1.01 ± 0.28 1.00 ± 0.41 0.674
TG (mmol/L)b 1.84 (1.39–2.42) 1.22 (1.19–1.34) 1.95 (1.53–2.20) 1.97 (1.45–2.89) 0.030
NEFA (mEq/L) 0.61 (0.50–0.70) 0.86 (0.79–0.93) 0.564 (0.49–0.65) 0.645 (0.52–0.74) 0.099
Glucose (mmol/L) 5.38 (4.83–6.22) 4.88 (4.66–6.22) 5.11 (4.77–5.55) 5.80 (5.13–6.80) 0.014
Insulin (pmol/L) 92.9 (57.1–173.6) 57.1 (49.3–173.6) 92.2 (60.5–152.8) 99.4 (63.2–178.2) 0.472
HOMA-IR 3.40 (1.94–6.50) 1.78 (1.53–4.66) 3.22 (1.91–4.97) 3.76 (2.12–7.53) 0.177
Data represented as mean ± s.d. or median (first quartile–third quartile). P values are shown for differences between the three SAF groups, significant  
P values were indicated in bold.
a24 patients were excluded from analysis due to use of statins. bOne patient is excluded as it had an extreme high value (TG = 16.14 mmol/L).
BMI, body mass index; CRP, C-reactive protein; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment-estimated insulin resistance; 
LDL, low-density lipoprotein; NAFL, nonalcoholic fatty liver; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis;  
NEFA, non-esterified fatty acids; T2D, type 2 diabetes; TG, triglycerides. 
Table 2 Distribution of the population according to the 
histological NAFLD components.
Histological components NAFLD n
Steatosis
 Steatosis <5% 5
 Steatosis 5–33% 31
 Steatosis >33–66% 18
 Steatosis >66% 24
Ballooning
 No balloon cells 33
 Few balloon cells 29
 Many balloon cells 16
Lobular inflammation
 No inflammatory foci (per 20× field) 29
 <2 inflammatory foci (per 20× field) 42
 2–4 inflammatory foci (per 20× field) 6
 >4 inflammatory foci (per 20× field) 1
Fibrosisa
 No fibrosis 17
 Perisinusoidal or (peri)portal fibrosis 39
 Perisinusoidal and (peri)portal fibrosis 17
 Bridging fibrosis 3
 Cirrhosis 1
aOne patient did not have a fibrosis score.
NAFLD, nonalcoholic fatty liver disease.
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and age, BMI and fibrosis score (F(2,65) = 3792; P = 0.028). 
The difference in HOMA-IR levels between fibrosis 
groups was independent of age and BMI (F(2,68) = 3620; 
P = 0.032); age, BMI and TG (F(2,66) = 3323; P = 0.042); and 
age, BMI and sex (F(2,67) = 3424; P = 0.038) but lost its 
significance when controlling for age, BMI and T2D status 
(F(2,67) = 2422, P = 0.097) and age, BMI and inflammation 
score (F(2,65) = 1061; P = 0.352).
Discussion
In this population of severely obese subjects, NAFLD 
severity according to NAS is associated with higher IR. 
Moreover, from the four histopathological components, 
lobular inflammation shows the strongest link with IR, 
whereas grade of fibrosis is no longer related to IR after 
controlling for inflammation score.
Only few other human studies investigated this topic 
using histological data. In accordance with our findings, Bril 
et al., who recruited subjects from the general population, 
found lower whole-body insulin clearance with increasing 
grade of inflammation (15). Similarly, Ballestri et al. and 
Park et al. also report a positive association between IR and 
lobular inflammation, although this was not found by 
Jung et al. and Petta et al. (11, 12, 13, 23). Also in line with 
our findings, all these studies, except for those by Jung 
et al. (23) and Bril et al. (15), report positive associations 
between indices of IR and fibrosis score (11, 12, 13, 24). 
However, none evaluated whether fibrosis is associated 
with IR independently of other NAFLD features, whereas 
in our cohort, fibrosis was no longer associated with IR 
when correcting for inflammation. Obviously, NAFLD 
is a progressive disease and inflammation is considered 
to be the precursor of fibrosis (25), which might 
also explain part of the divergence in these findings. 
Further, contrasting our findings and those of Park et al.  
(in 24 children with NAFLD) (12), other studies showed 
higher HOMA-IR in patients with a higher grade of 
steatosis or ballooning (11, 12, 13, 14, 24, 26), whereas Bril 
et al. found that hepatic IR already is present in subjects 
with simple steatosis and that ballooning, but not steatosis 
grade, was associated with whole-body IR (15). Differences 
in methodology and populations could contribute to 
these discrepant results. We recruited patients who met 
the criteria for undergoing GBS and willing to undergo 
a liver biopsy, while other studies recruited subjects 
already diagnosed with NAFLD. More or less as a result 
of these different recruitment strategies, our population 
presented with lesser NAFLD severity, with 33.3% of our 
population having NASH while in the populations of 
Petta et  al. and Jung et  al. 62.2 and 66.7% have NASH, 
Figure 1
The correlation between NAS and HOMA-IR levels in a population with 
obesity. HOMA-IR, homeostasis model assessment-estimated insulin 
resistance.
Figure 2
Differences in HOMA-IR levels between 
histological NAFLD groups. HOMA-IR according to 
steatosis score (panel A), ballooning score (panel 
B), lobular inflammation score (panel C) and 
fibrosis score (panel D). For all panels two data 
points with a HOMA-IR level above 20 are not 
shown in the boxplots. In panel C the group with 
more than four inflammatory foci only consisted 
of one patient and is excluded from analysis and 
the graph. In panel D the groups with scores 3 
and 4 are excluded from analysis and this figure 
as those groups consisted of three and one 
patient, respectively. Statistically significant 
differences are indicated in bold in the figures. 
HOMA-IR, homeostasis model assessment-
estimated insulin resistance; K-W, Kruskal–Wallis.
A B
C D
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respectively (13, 23). Further, not all studies corrected 
for BMI, whereas due to the recruitment strategy our 
population is more obese and also more insulin resistant 
(although our participants’ values corroborate with those 
of similar cohorts (11, 23, 24, 27)), while other studies 
even included non-obese subjects. Finally, although a 
recent meta-analysis showed no relation between grade 
of obesity and NAFLD severity (28), previous reports 
suggested higher BMI in patients with NASH compared 
to those with NAFL (11, 12, 13, 14, 23, 24, 26). Subjects 
with NASH in our study, however, tended to present 
with lower BMI than participants without NASH which 
raises the question whether our NASH cohort reflects 
a subgroup of patients who present with more severe 
consequences of obesity. Similarly, prevalence of T2DM 
was highest in those patients with NASH. This could be 
a confounding factor and when excluding these patients 
from analysis the positive association between HOMA-IR 
and NAS lost significance (data not shown). However, as 
diagnosis of T2D is based on arbitrary cut-offs, while IR is 
a physiological condition and all patients stopped intake 
of antidiabetic drugs timely before sampling; this will not 
have affected our main findings. In summary, our study is 
the first to address the relation between IR and components 
of NAFLD in a homogenous adult population with severe 
obesity (BMI >35 kg/m2) and suggests that in this specific 
population hepatic inflammation is the component most 
strongly associated with IR.
Several pathophysiological processes might explain 
these findings. In obesity-related IR, diminished inhibition 
of hormone-sensitive lipase will lead to enhanced efflux 
of FFA from adipocytes, while the compensatory systemic 
hyperinsulinaemia increases hepatic FFA uptake and 
activates lipogenic genes (29, 30, 31). Once excessive 
influx of FFA overflows the hepatocytes’ capacity to 
store them as TG in lipid droplets, accumulation of 
diacylglycerols (DAGs) will impair insulin signalling 
causing decreases in hepatic glycogen synthesis and 
increases in gluconeogenesis (6, 8, 30, 32, 33, 34, 35, 
36). As histological grading of hepatic steatosis is based 
on the amount of lipid droplets and not intracellular 
DAG content (which we were unable to reassess in our 
samples), this could explain the absent association 
between grade of steatosis and IR in our cohort. Further, 
as DAG accumulation also leads to production of reactive 
oxygen species causing hepatic inflammation (37, 38), 
lobular inflammation seems a consequence rather than a 
cause of obesity-related IR. A view which is also supported 
by some animal data (39). However, there is also evidence 
suggesting a contribution of hepatic inflammation to 
systemic IR. For instance, in hepatitis C virus infection, 
hepatic inflammation increases circulating levels of 
interleukin 1, tumour necrosis factor alpha and interleukin 
6, which all can stimulate IR (40, 41). In addition, other 
processes such as alterations in hepatokine secretion or 
ceramide metabolism probably also contribute to the 
association between hepatic inflammation and IR (42, 43).
Although our study is limited by its cross-sectional 
design and the lack of a blinded and single histopathological 
evaluation, our findings are of clinical importance (44). 
For instance, clinical NAFLD evaluation still relies in large 
part on imaging procedures that focus on hepatic fat 
content and to a lesser extent on fibrosis whereas grade 
of inflammation is more difficult to assess. However, in 
contrast to fibrosis, inflammation is considered to be a 
reversible state of NAFLD so accurate estimation of this 
component of NAFLD is of clinical relevance. Moreover, 
from our findings it follows that obese subjects with NAFL 
who proceed to NASH should be screened for IR, and 
that, in addition to screening for NAFLD in patients with 
T2D, obese patients with uncomplicated IR should also be 
evaluated for NALFD (44, 45).
In conclusion, in subjects with severe obesity, IR is 
most strongly associated with lobular inflammation, 
more than with other histopathologic components of 
NAFLD. This may reflect a direct relation between hepatic 
Table 3 Correlations between individual histological components and characteristics of glucose metabolism.
Steatosis (n = 78) Inflammation (n = 78) Ballooning (n = 78) Fibrosis (n = 77)
Age (years) 0.096 (0.403) 0.040 (0.726) 0.101 (0.380) 0.097 (0.403)
BMI (kg/m2) −0.053 (0.647) −0.085 (0.461) −0.195 (0.086) 0.008 (0.943)
TG (mmol/L)a 0.251 (0.028) 0.232 (0.042) 0.171 (0.137) 0.242 (0.035)
NEFA (mEq/L) −0.144 (0.305) 0.145 (0.299) −0.071 (0.612) 0.090 (0.527)
Glucose (mmol/L) 0.173 (0.130) 0.226 (0.046) 0.263 (0.020) 0.299 (0.008)
Insulin (pmol/L) 0.170 (0.137) 0.293 (0.009) 0.152 (0.183) 0.280 (0.014) 
HOMA-IR 0.186 (0.102) 0.327 (0.004) 0.187 (0.101) 0.302 (0.008) 
Results are represented as the correlation coefficient (P value). Significant P values are indicated in bold.
aOne patient is excluded as it had an extreme high value (TG = 16.14 mmol/L).
BMI, body mass index; TG, triglycerides; NEFA, non-esterified fatty acids; HOMA-IR, homeostasis model assessment-estimated insulin resistance.
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inflammation and systemic insulin signalling but could 
also be explained by a subgroup of patients which is more 
prone to develop obesity-related consequences.
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